Practice guideline 'prostate cancer: Diagnosis and treatment';Richtlijn 'prostaatcarcinoom: Diagnostiek en behandeling'

Nederlands Tijdschrift voor Geneeskunde

Volumn 152, Issue 32, 2008, Pages 1771-1775

  De Reijke, Th M ^a   Battermann, J J ^b   Van Moorselaar, R J A ^c   De Jong, I J ^d   Visser, A P ^e   Burgers, J S ^f  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e HELEN DOWLING INSTITUTE   (Netherlands)

^f Dutch Institute for Healthcare Improvement CBO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; ESTROGEN; GONADORELIN DERIVATIVE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

BRACHYTHERAPY; CASTRATION; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HUMAN; PRACTICE GUIDELINE; PROSTATE CANCER; PROSTATECTOMY; REVIEW; TRANSRECTAL ULTRASONOGRAPHY;

BRACHYTHERAPY; COMBINED MODALITY THERAPY; HUMANS; LIFE EXPECTANCY; MALE; MEDICAL ONCOLOGY; NEOPLASM STAGING; NETHERLANDS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SOCIETIES, MEDICAL;

EID: 49749103271     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Oers JAM van, redacteur. Gezondheid op koers? Volksgezondheid Toekomst Verkenning 2002. RIVM rapportnr 270551001. Houten: Bohn Stafleu van Loghum; 2002.
2. Everdingen JJE van, Burgers JS, Assendelft WJJ, Swinkels JA, Barneveld TA van, Klundert JLM van, redacteuren. Evidence-based richtlijnontwikkeling. Een leidraad voor de praktijk. Houten: Bohn Stafleu van Loghum; 2004.
3. Hamilton W, Sharp D. Symptomatic diagnosis of prostate cancer in primary care: a structured review. Br J Gen Pract. 2004;54:617-21.
4. Johns LE, Houlston RS. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int. 2003;91:789-94.
5. Schröder FH, Maas P van der, Beemsterboer P, Kruger AB, Hoedemaker R, Rietbergen J, et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 1998;90:1817-23.
6. Ruijter ET, Kaa CA van de, Schalken JA, Debruyne FM, Ruiter DJ. Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol. 1996;180:295-9.
7. Sobin LH, Wittekind Ch, editors. TNM classification of malignant tumours. 6th ed. New York: Wiley-Liss; 2002.
8. Gleason DF. Histologic grading in prostatic carcinoma. In: Bostwick DG, editor. Pathology of the prostate. New York: Churchill Livingstone; 1990. p. 83-93.
9. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293:2095-101.
10. Vicini FA, Martinez A, Hanks G, Hanlon A, Miles B, Kernan K, et al. An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up. Cancer. 2002;95:2126-35.
11. Schapira MM, Meade C, Nattinger AB. Enhanced decision-making: the use of a videotape decision-aid for patients with prostate cancer. Patient Educ Couns. 1997;30:119-27.
12. Adolfsson J, Steineck G, Hedlund PO. Deferred treatment of locally advanced nonmetastatic prostate cancer: a long-term followup. J Urol. 1999;161:505-8.
13. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma. Long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005;61:1285-90.
14. Cagiannos I, Karakiewicz P, Eastham JA, Ohori M, Rabbani F, Gerigk C, et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol. 2003;170:1798-803.
15. Hayes BS, Pollack A. Parameters for treatment decisions for salvage radiation therapy. J Clin Oncol. 2005;23:8204-11.
16. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37:1035-41.
17. Stephenson AJ, Eastham JA. Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. J Clin Oncol. 2005;23:8198-203.
18. Samson DJ, Seidenfeld J, Schmitt B, Hasselblad V, Albertsen PC, Bennett CL, et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer. 2002;95:361-76.
19. Visser GE, Klinken PC van, Postma-Schuit FCE. Inventarisatie voorlichtings- en ondersteuningsbehoefte van patiënten met prostaatkanker en hun partners. Amsterdam: Integraal Kankercentrum Amsterdam; 1997.
20. Chaplin BJ, Wildhagen MF, Schröder FH, Kirkels WJ, Bangma CH. Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up. Eur Urol. 2005;48:906-10.
21. Voerman AE, Fischer MJ, Visser AP, Andel G van, Garssen B, Bensing JM. Prostaatkanker: een literatuuroverzicht van psychosociale problemen en psychosociale interventies. Gedrag & Gezondheid. 2004;32:251-70.
22. Stone NN, Stock RG. Complications following permanent prostate brachytherapy. Eur Urol. 2002;41:427-33.